 BOTHELL, Wash., May 07, 2021 GLOBE NEWSWIRE -- Cocrystal Pharma, Inc. Nasdaq: COCP, Cocrystal or the Company, a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, coronaviruses, hepatitis C viruses and noroviruses, today announced the closing of its previously announced public offering of 26,000,000 shares of common stock of the Company, at a price to the public of 1.54 per share, less underwriting discounts and commissions. 